Defining a new molecular basis of systemic lupus erythematosus through transcriptional profiling

References

• Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA100(5), 2610–2615 (2003).
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med.197(6), 711–723 (2003).
   PubMed Web of Science ®Google Scholar
• Han GM, Chen SL, Shen N et al. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun.4(3), 177–186 (2003).
   PubMed Web of Science ®Google Scholar
• Grossman JM, Kalunian KC. Definition, classification, activity, and damage indices. In: Dubois’ Lupus Erythematosus. Wallace DH (Ed.). Lippincott Williams & Wilkins, PA, USA 19–31 (2002).
   Google Scholar
• Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for SLE. Nat. Rev.3(12), 1036–1046 (2004).
   Google Scholar
• Wallace DJ. Biologic and innovative therapies for systemic lupus erythematosus. Rhuem. Dis. Clin. Updates2(1), 1–9 (2007).
   Google Scholar
• Eisenberg R. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr. Metab. Immune Disord. Drug Targets6(4), 345–350 (2006).
   PubMedGoogle Scholar
• Furie R, Lisse J, Merrill JT et al. Belimumab (fully humanized monoclonal antibody to B-lymphocyte stimulator (BLyS)) improves or stabilizes SLE activity in a multicenter Phase 2 trial. Arthritis Rheum.54(9 Suppl.), S258 (2006).
   Google Scholar
• Hooks JJ, Moutsopoulos HM, Geis SA et al. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med.301(1), 5–8 (1979).
   PubMed Web of Science ®Google Scholar
• Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science216(4544), 429–431 (1982).
   PubMed Web of Science ®Google Scholar
• Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J. Intern. Med.227(3), 207–210 (1990).
   PubMed Web of Science ®Google Scholar
• Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med.115(3), 178–183 (1991).
   PubMed Web of Science ®Google Scholar
• Wandl UB, Nagel-Hiemke M, May D et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin. Immunol. Immunopathol.65(1), 70–74 (1992).
   PubMedGoogle Scholar
• Kirou KA, Lee C, George S et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum.50(12), 3958–3967 (2004).
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S et al. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum.52(5), 1491–1503 (2005).
   PubMed Web of Science ®Google Scholar
• Peterson KS, Huang JF, Zhu J et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest.113(12), 1722–1733 (2004).
   PubMed Web of Science ®Google Scholar
• Toukap AN, Galant C, Theate I et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum.56(5), 1579–1588 (2007).
   PubMedGoogle Scholar
• Wenzel J, Uerlich M, Worrenkamper E et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br. J. Dermatol.153(5), 1011–1015 (2005).
   PubMed Web of Science ®Google Scholar
• Blomberg S, Eloranta ML, Cederblad B et al. Presence of cutaneous interferon-α producing cells in patients with systemic lupus erythematosus. Lupus10(7), 484–490 (2001).
   PubMed Web of Science ®Google Scholar
• Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon- α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol.159(1), 237–243 (2001).
   PubMed Web of Science ®Google Scholar
• Bauer JW, Baechler EC, Petri M et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med.3(12), e491 (2006).
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet354(9194), 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. J. Rheumatol.33(6), 1075–1081 (2006).
   PubMed Web of Science ®Google Scholar
• Chuntharapai A, Lai J, Huang X et al. Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine15(5), 250–260 (2001).
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med.343(22), 1586–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med.340(4), 253–259 (1999).
   PubMed Web of Science ®Google Scholar
• Jiang Y, Genant HK, Watt I et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum.43(5), 1001–1009 (2000).
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N. Engl. J. Med.350(21), 2167–2179 (2004).
   PubMed Web of Science ®Google Scholar
• Dzionek A, Sohma Y, Nagafune J et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med.194(12), 1823–1834 (2001).
   PubMed Web of Science ®Google Scholar
• Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum.48(9), 2524–2532 (2003).
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Pinkus JL, Pinkus GS et al. Interferon-α/β-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol.57(5), 664–678 (2005).
   PubMed Web of Science ®Google Scholar
• Bave U, Nordmark G, Lovgren T et al. Activation of the type I interferon system in primary Sjogren’s syndrome: a possible etiopathogenic mechanism. Arthritis Rheum.52(4), 1185–1195 (2005).
   Google Scholar
• Devendra D, Eisenbarth GS. Interferon α – a potential link in the pathogenesis of viral-induced Type 1 diabetes and autoimmunity. Clin. Immunol.111(3), 225–233 (2004).
   PubMed Web of Science ®Google Scholar
• Lande R, Giacomini E, Serafini B et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J. Immunol.173(4), 2815–2824 (2004).
   PubMed Web of Science ®Google Scholar
• Nestle FO, Conrad C, Tun-Kyi A et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J. Exp. Med.202(1), 135–143 (2005).
   PubMed Web of Science ®Google Scholar
• Takii Y, Nakamura M, Ito M et al. Enhanced expression of type I interferon and Toll-like receptor-3 in primary biliary cirrhosis. Lab. Invest.85(7), 908–920 (2005).
   PubMed Web of Science ®Google Scholar
• Baechler EC, Bauer JW, Slattery CA et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol. Med.13, 59–68 (2007).
   PubMed Web of Science ®Google Scholar
• Emamian ES, Leon J, Rao S et al. Over-expression of interferon-inducible genes is highly correlated with sicca manifestations and autoantibody levels in Sjogren’s syndrome. Arthritis Rheum.50(9 Suppl.), S446 (2004).
   Google Scholar
• van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis.66(8), 1008–1014 (2007).
   PubMed Web of Science ®Google Scholar
• Tan FK, Zhou X, Mayes MD et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford),45(6), 694–702 (2006).
   PubMedGoogle Scholar
• van Baarsen LG, van der Pouw Kraan TC, Kragt JJ et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun.7(6), 522–531 (2006).
   PubMedGoogle Scholar
• Reichlin M, Harley JB. Antibodies to RO/SSA and LA/SSB. In: Dubois’ Lupus Erythematosus. Wallace DH (Ed.). Lippincott Williams & Wilkins, PA, USA 467–480 (2002).
   Google Scholar
• Greenberg SA, Sanoudou D, Haslett JN et al. Molecular profiles of inflammatory myopathies. Neurology59(8), 1170–1182 (2002).
   PubMed Web of Science ®Google Scholar
• Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain128(Pt 8), 1887–1896 (2005).
   PubMed Web of Science ®Google Scholar
• Tezak Z, Hoffman EP, Lutz JL et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J. Immunol.168(8), 4154–4163 (2002).
   PubMed Web of Science ®Google Scholar
• Zhou X, Dimachkie MM, Xiong M, Tan FK, Arnett FC. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med. Sci. Monit.10(7), BR191–BR197 (2004).
   PubMed Web of Science ®Google Scholar
• Solomon DH, Goodson NJ, Katz JN et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis.65(12), 1608–1612 (2006).
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Ortmann WA et al. Gene signatures in peripheral blood predict future disease activity in patients with systemic lupus erythematosus. Arthritis Rheum.52(9 Suppl.), S700 (2005).
   Google Scholar
• Dorner T, Lipsky PE. Correlation of circulating CD27 high plasma cells and disease activity in systemic lupus erythematosus. Lupus13(5), 283–289 (2004).
   PubMed Web of Science ®Google Scholar
• Asmal M, Colgan J, Naef F et al. Production of ribosome components in effector CD4+ T cells is accelerated by TCR stimulation and coordinated by ERK-MAPK. Immunity19(4), 535–548 (2003).
   PubMedGoogle Scholar
• Liossis SN, Vassilopoulos D, Kovacs B, Tsokos GC. Immune cell biochemical abnormalities in systemic lupus erythematosus. Clin. Exp. Rheumatol.15(6), 677–684 (1997).
   PubMed Web of Science ®Google Scholar
• Gergely P Jr, Grossman C, Niland B et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum.46(1), 175–190 (2002).
   PubMed Web of Science ®Google Scholar
• Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol.16(6), 663–669 (2004).
   PubMed Web of Science ®Google Scholar
• Nagy G, Barcza M, Gonchoroff N, Phillips PE, Perl A. Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J. Immunol.173(6), 3676–3683 (2004).
   PubMed Web of Science ®Google Scholar
• Liu CC, Manzi S, Ahearn JM. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr. Opin. Rheumatol.17(5), 543–549 (2005).
   PubMed Web of Science ®Google Scholar
• Rus V, Atamas SP, Shustova V et al. Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin. Immunol.102(3), 283–290 (2002).
   PubMed Web of Science ®Google Scholar
• Maas K, Chan S, Parker J et al. Cutting edge: molecular portrait of human autoimmune disease. J. Immunol.169(1), 5–9 (2002).
   PubMed Web of Science ®Google Scholar
• Rus V, Chen H, Zernetkina V et al. Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive disease. Clin. Immunol.112(3), 231–234 (2004).
   PubMed Web of Science ®Google Scholar
• Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin. Exp. Immunol.138(1), 164–170 (2004).
   PubMed Web of Science ®Google Scholar
• Pereira E, Tamia-Ferreira MC, Cardoso RS et al. Immunosuppressive therapy modulates T lymphocyte gene expression in patients with systemic lupus erythematosus. Immunology113(1), 99–105 (2004).
   PubMedGoogle Scholar
• Xu L, Zhang L, Yi Y, Kang HK, Datta SK. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat. Med.10(4), 411–415 (2004).
   PubMedGoogle Scholar